interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Aripiprazole

Generic competition · all medicines · read 12 November 2026

Is there a generic of Aripiprazole, and who makes it?

Aripiprazole appears in 7 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 22 generic makers listed as marketed across them. 3 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 8.9 and 12.4 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Aripiprazole7 dosage-form groups in the Orange Book
22generic makers listed
  1. Aripiprazole appears in 7 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 22 generic makers listed as marketed across them.
  2. 3 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 8.9 and 12.4 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Abilify. 14 generic makers with 81 generic products listed as marketed; the first generic approval is dated 28 April 2015.

2000200520102015202020252030014brand 2002Alembic Pharmaceuticals Ltd, first approval 28 April 2015Hetero Labs Ltd Unit V, first approval 28 April 2015Torrent Pharmaceuticals Ltd, first approval 28 April 2015Aurobindo Pharma Ltd, first approval 8 October 2015Amneal Pharmaceuticals, first approval 17 June 2016Ajanta Pharma Ltd, first approval 12 September 2016Sciegen Pharmaceuticals Inc, first approval 29 September 2016Macleods Pharmaceuticals Ltd, first approval 7 October 2016Accord Healthcare Inc, first approval 7 December 2016Orbion Pharmaceuticals Private Ltd, first approval 23 May 2017Prinston Pharmaceutical Inc, first approval 4 December 2017Alkem Laboratories Ltd, first approval 21 February 2019Unichem Laboratories Ltd, first approval 1 December 2021Sunshine Lake Pharma Co Ltd, first approval 2 October 2023data datePatent 8759350 listed to expire 2 March 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Alembic Pharmaceuticals Ltd28 April 20156
Hetero Labs Ltd Unit V28 April 20156
Torrent Pharmaceuticals Ltd28 April 20156
Aurobindo Pharma Ltd8 October 20156
Amneal Pharmaceuticals17 June 20166
Ajanta Pharma Ltd12 September 20166
Sciegen Pharmaceuticals Inc29 September 20166
Macleods Pharmaceuticals Ltd7 October 20166
Accord Healthcare Inc7 December 20166
Orbion Pharmaceuticals Private Ltd23 May 20176
Prinston Pharmaceutical Inc4 December 20176
Alkem Laboratories Ltd21 February 20196

2 more makers are listed in the data.

Patents and exclusivities still listed

  • 2 March 2027Patent 8759350

Tablet, Orally Disintegrating, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 4 generic makers with 10 generic products listed as marketed; the first generic approval is dated 28 April 2015.

20052010201520202025203004brand 2006Alembic Pharmaceuticals Ltd, first approval 28 April 2015Orbion Pharmaceuticals Private Ltd, first approval 11 December 2017Sciegen Pharmaceuticals Inc, first approval 18 April 2018Square Pharmaceuticals Ltd, first approval 28 August 2018data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Alembic Pharmaceuticals Ltd28 April 20152
Orbion Pharmaceuticals Private Ltd11 December 20172
Sciegen Pharmaceuticals Inc18 April 20182
Square Pharmaceuticals Ltd28 August 20184

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Oral

Four or more generic makers listed

Every brand product here is listed as discontinued. 9 generic makers with 9 generic products listed as marketed; the first generic approval is dated 14 August 2015.

200020052010201520202025203009brand 2004Amneal Pharmaceuticals, first approval 14 August 2015Lannett Co Inc, first approval 14 August 2015Apotex Inc, first approval 30 September 2015Aurobindo Pharma Ltd, first approval 29 January 2019Vistapharm Llc, first approval 26 December 2019Chartwell Rx Sciences Llc, first approval 25 October 2022Rubicon Research Ltd, first approval 27 October 2022Hetero Labs Ltd Unit Iii, first approval 1 November 2023Quagen Pharmaceuticals Llc, first approval 22 October 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Amneal Pharmaceuticals14 August 20151
Lannett Co Inc14 August 20151
Apotex Inc30 September 20151
Aurobindo Pharma Ltd29 January 20191
Vistapharm Llc26 December 20191
Chartwell Rx Sciences Llc25 October 20221
Rubicon Research Ltd27 October 20221
Hetero Labs Ltd Unit Iii1 November 20231
Quagen Pharmaceuticals Llc22 October 20251

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Film, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Opipza. No generic is listed as marketed.

20202025203020352040204501brand 2024data datePatent 11331315 listed to expire 3 November 2040Patent 11701352 listed to expire 15 December 2041
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 3 November 2040Patent 11331315 drug product
  • 15 December 2041Patent 11701352 drug product

For Suspension, Extended Release, Intramuscular

Brand listed, no generic listed as marketed

Brand listed as marketed: Abilify Maintena Kit. No generic is listed as marketed (2 generic products listed as discontinued).

2010201520202025203020352040204501brand 2013data datePatent 11344547 listed to expire 24 September 2033Patent 11400087 listed to expire 24 September 2033Patent 10980803 listed to expire 24 September 2033Patent 11154553 listed to expire 24 September 2033Patent 10525057 listed to expire 8 March 2034Patent 11648347 listed to expire 6 April 2034Patent 12691056 listed to expire 1 April 2041
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 24 September 2033Patent 11344547
  • 24 September 2033Patent 11400087
  • 24 September 2033Patent 10980803
  • 24 September 2033Patent 11154553
  • 8 March 2034Patent 10525057
  • 6 April 2034Patent 11648347 drug product
  • 1 April 2041Patent 12691056

Suspension, Extended Release, Intramuscular

Brand listed, no generic listed as marketed

Brand listed as marketed: Abilify Asimtufii. No generic is listed as marketed.

202020252030203501brand 2023data datePatent 12016927 listed to expire 23 April 2033Patent 11638757 listed to expire 23 April 2033Patent 11097007 listed to expire 23 April 2033Patent 10517951 listed to expire 23 April 2033
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 23 April 2033Patent 12016927 drug product
  • 23 April 2033Patent 11638757 drug product
  • 23 April 2033Patent 11097007 drug product
  • 23 April 2033Patent 10517951 drug product

Injectable, Intramuscular

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

20052010201520202025203001brand 2006data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.